Search Results
Feb 02, 2026, 08:30 ET Johnson Controls previews YORK YK-HT two-stage economized centrifugal chiller at AHR Expo, delivering energy, water and space savings
sustainable buildings, is previewing the high-density, compact YORK YK-HT two-stage economized centrifugal chiller at AHR Expo 2026 in Las Vegas. Engineered for data centers and large industrial, pharmaceutical and healthcare campuses, the YK‑HT delivers the industry's widest operating range from a single driveline,
More news about: Johnson Controls International plc
Jan 31, 2026, 11:34 ET Six-figure salary, no classroom: Inside the rise of the education architect
[email protected]: +44 (0) 1865 435 135 Tutors International, Prama House, 267 Banbury Road, Oxford OX2 7HT, UK
More news about: Tutors International
Jan 30, 2026, 08:38 ET Incheon National University Develop Novel Eco-Friendly High-Performance Gas Sensors
University in South Korea has developed novel eco-friendly OFET gas sensors. These sensors utilize blended polymer films combining poly(3-hexylthiophene) (P3HT), a widely used organic semiconductor, and poly(butylene succinate) (PBS). "Using PBS, a well-known biodegradable polymer, and effective solvent engineering,
More news about: Incheon National University
Jan 26, 2026, 21:04 ET Anuncio de los galardonados con el Premio Japón 2026
https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202601142440/_prw_PI3fl_n3HT0jm9.jpg Para el Premio Japón de este año, la Prof. Dwork está siendo reconocida por su contribución a la
More news about: Japan Prize Foundation
Jan 26, 2026, 20:50 ET Laureados do Japan Prize 2026 são anunciados
https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202601142440/_prw_PI3fl_n3HT0jm9.jpg Neste ano, a professora Cynthia Dwork está sendo reconhecida pelo Japan Prize por sua contribuição
More news about: Japan Prize Foundation
Jan 26, 2026, 20:46 ET Preisträger des Japan-Preises 2026 bekannt gegeben
https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202601142440/_prw_PI3fl_n3HT0jm9.jpg Für den diesjährigen Japan-Preis wird Prof. Dwork für ihren Beitrag zur führenden Forschung zum
More news about: Japan Prize Foundation
Jan 23, 2026, 04:41 ET Se anuncian los ganadores del Premio Japón 2026
https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202601142440/_prw_PI3fl_n3HT0jm9.jpg En el Premio Japón de este año, la profesora Dwork recibe un reconocimiento por su contribución
More news about: Japan Prize Foundation
Jan 23, 2026, 04:37 ET Annonce des lauréats du Prix du Japon 2026
https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202601142440/_prw_PI3fl_n3HT0jm9.jpg Pour le Prix du Japon de cette année, Mme Dwork est récompensée pour sa contribution à la recherche
More news about: Japan Prize Foundation
Jan 23, 2026, 04:23 ET 2026年日本國際賞得主揭曉
Zhijian "James" Chen教授照片：https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202601142440/_prw_PI3fl_n3HT0jm9.jpg 在本年度的日本國際賞評選中
More news about: Japan Prize Foundation
Jan 22, 2026, 08:13 ET Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
symptoms, underscores the potential of HT-001 to improve the treatment experience for cancer patients receiving EGFR inhibitors. We are encouraged by the breadth and consistency of these findings as the CLEER-001 trial continues."About HT-001HT-001 is Hoth Therapeutics' proprietary
More news about: Hoth Therapeutics, Inc.
Jan 22, 2026, 01:00 ET 2026 Japan Prize Laureates Announced
https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202601142440/_prw_PI3fl_n3HT0jm9.jpg For this year's Japan Prize, Prof. Dwork is being recognized for her contribution to leading research
More news about: Japan Prize Foundation
Jan 22, 2026, 01:00 ET 2026 Japan Prize Laureates Announced
https://cdn.kyodonewsprwire.jp/prwfile/release/M000319/202601142440/_prw_PI3fl_n3HT0jm9.jpg For this year's Japan Prize, Prof. Dwork is being recognized for her contribution to leading research
More news about: Japan Prize Foundation
Jan 21, 2026, 08:13 ET Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
protection in China enhances the long-term strategic and commercial value of HT-KIT as we continue advancing this program as a differentiated cancer-fighting approach."HT-KIT: Targeting Cancer Through Apoptosis PathwaysHT-KIT is designed to disrupt aberrant KIT-driven signaling, a pathway
More news about: Hoth Therapeutics, Inc.
Jan 20, 2026, 09:00 ET HT Vet's VISTA iQ™ Introduces New Cancer Diagnostic Service, Unlocking $130K in Annual Revenue for Veterinary Clinics
HT Vet, the veterinary health technology company behind the first non-invasive, cancer detection tool for lumps and bumps on dogs, today announced the launch of VISTA iQ™, the next-generation AI-powered successor to the original HT Vista scanner. VISTA iQ builds on
More news about: HT Vet
Jan 16, 2026, 08:00 ET New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
episodes associated with bipolar I or II disorder. While the mechanism of action is unknown, CAPLYTA® is characterized by high serotonin 5-HT2A receptor occupancy and moderate amounts of dopamine D2 receptor occupancy at therapeutic doses. CAPLYTA® does not need dose
More news about: Johnson & Johnson
Jan 15, 2026, 08:17 ET Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
biopharmaceutical company developing therapies for serious and underserved conditions, today announced it has achieved a major European regulatory milestone for its HT-001 clinical program targeting cancer patients undergoing EGFR inhibitor therapies.
More news about: Hoth Therapeutics, Inc.
Jan 14, 2026, 22:03 ET MATSON ANNOUNCES PRELIMINARY 4Q25 RESULTS, PROVIDES 2026 OUTLOOK AND ANNOUNCES 4Q25 EARNINGS CALL DATE
Time:4:30 p.m. ET / 1:30 p.m. PT / 11:30 a.m. HTThe conference call will be broadcast live along with an additional slide presentation on the Company's website at
More news about: Matson, Inc.
Jan 14, 2026, 17:10 ET Transneural Therapeutics Presents Preclinical Data on Lead Candidate TN-001 at 64th Annual Meeting of ACNP (2026)
Findings:TN-001 is a potent partial agonist at the 5HT2A receptor, and full antagonist at the 5HT2B receptor.5-HT2B agonism is a common off-target activity among many 5-HT2A agonists and confers significant risk for long-term cardiac valvular
More news about: Transneural Therapeutics, Inc.
Jan 13, 2026, 23:20 ET Alamar Biosciences Umumkan Peluncuran NULISAqpcr™ AD 5-plex Assay Untuk Memajukan Deteksi Biomarker Berbasis Darah Dalam Penelitian Penyakit Alzheimer
bidang ilmu hayati yang berkomitmen untuk mendukung proteomik presisi guna mendeteksi penyakit lebih dini. Dengan memanfaatkan teknologi NULISA™ dan ARGO™ HT System eksklusifnya, platform Alamar dirancang untuk menyediakan sensitivitas amat sangat tinggi dan mengatasi berbagai keterbatasan utama yang dialami
More news about: Alamar Biosciences, Inc.
Jan 13, 2026, 13:06 ET Alamar Biosciences 宣佈推出 NULISAqpcr™ AD 五重檢測套組 (5NULISAqpcr AD 5-plex Assay)，推動阿茲海默症研究中基於血液的生物標記檢測技術發展
www.alamarbio.com。Alamar Biosciences, Inc. 簡介Alamar Biosciences 是一間私營生命科學公司，致力於為精準蛋白質體提供動力，以便最早發現疾病。憑藉其專有的 NULISA™ 技術及 ARGO™ HT 系統，Alamar 的平台旨在提供超高靈敏度檢測，解決現有技術在精準蛋白質組學應用上的關鍵局限。如欲了解更多資料，請瀏覽
More news about: Alamar Biosciences, Inc.
Jan 13, 2026, 10:55 ET Alamar Biosciences công bố ra mắt bộ xét nghiệm NULISAqpcr™ AD 5-plex, thúc đẩy khả năng phát hiện dấu ấn sinh học thông qua máu trong nghiên cứu bệnh Alzheimer
hoạt động trong lĩnh vực khoa học sự sống chuyên phát triển công nghệ proteomics chính xác nhằm giúp phát hiện bệnh sớm nhất. Tận dụng hệ thống ARGO™ HT và công nghệ NULISA™ độc quyền, công nghệ của Alamar được thiết kế để mang lại độ nhạy siêu cao và khắc phục những hạn chế mấu chốt của các công nghệ
More news about: Alamar Biosciences, Inc.
Jan 13, 2026, 09:21 ET Alamar Biosciences gibt die Einführung des NULISAqpcr™ AD 5-plex-Assays bekannt, der die Erkennung von Biomarkern im Blut in der Alzheimer-Forschung vorantreibt
widmet, um die frühestmögliche Erkennung von Krankheiten zu ermöglichen. Die Plattform von Alamar nutzt die firmeneigene NULISA™-Technologie und das ARGO™ HT System und wurde entwickelt, um eine extrem hohe Empfindlichkeit zu erzielen und die wesentlichen Einschränkungen bestehender Technologien zu überwinden,
More news about: Alamar Biosciences, Inc.
Jan 13, 2026, 08:00 ET Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
CAPLYTA® is unknown, the efficacy of CAPLYTA® could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.About SeltorexantSeltorexant, an investigational
More news about: Johnson & Johnson
Jan 13, 2026, 05:36 ET 알라마 바이오사이언스, NULISAqpcr™ AD 5-플렉스 어세이 출시 발표...알츠하이머병 연구 시 혈액 기반 바이오마커 검출 진일보
www.alamarbio.com에서 확인할 수 있다.알라마 바이오사이언스 소개알라마 바이오사이언스는 정밀 단백질체학을 통해 질병 조기 발견 기술을 연구하는 비상장 생명과학 기업이다. 알라마의 플랫폼은 독자 개발한 NULISA™ 기술과 ARGO™ HT 시스템을 활용하여 감도가 매우 높으며, 기존 기술의 주요 한계점을 극복해 정밀 단백질체학을 실현한다. 자세한 사항은
More news about: Alamar Biosciences, Inc.
Jan 13, 2026, 04:09 ET Alamar Biosciences anuncia el lanzamiento del ensayo NULISAqpcr™ AD 5-plex
dedicada a impulsar la proteómica de precisión para la detección temprana de enfermedades. Gracias a su tecnología patentada NULISA™ y al sistema ARGO™ HT, la plataforma de Alamar está diseñada para ofrecer una sensibilidad ultraalta y abordar las principales limitaciones de las tecnologías existentes para
More news about: Alamar Biosciences, Inc.